Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

60.48 -2.41 (-3.82%)
Streaming Delayed Price Updated: 1:11 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
1 Biotech Stock Set to Rebound in 2026 ↗
The Wegovy maker is coming off a dismal showing in 2025, but it's a legitimate 2026 rebound candidate. 
Via The Motley Fool
News headline image
1 Pharmaceutical Stock Set to Rebound in 2026 ↗
Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026. 
Via The Motley Fool
News headline image
2 Pharmaceutical Stocks Set to Rebound in 2026 ↗
There might be massive upside ahead for these drugmakers. 
Via The Motley Fool
News headline image
Where Will Eli Lilly Be in 10 Years? ↗
Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever. 
Via The Motley Fool
Topics ETFs Intellectual Property
Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week ↗
Via Stocktwits
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Demonstrates a Strong Dividend Profile Backed by High Profitability ↗
Via Chartmill
NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’ ↗
Via Stocktwits
News headline image
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? ↗
Both companies may succeed in this industry. 
Via The Motley Fool
News headline image
Prediction: This Healthcare Stock Could Soar by 40% in 2026 ↗
This pharmaceutical giant has recently caught fire, and the stock's run is likely just beginning. 
Via The Motley Fool
News headline image
3 Growth Stocks to Invest $1,000 in Right Now ↗
It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Dump Eli Lilly's Shares After This Setback? ↗
The company got some bad news to start 2026. 
Via The Motley Fool
News headline image
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of... 
Via Finterra
Topics Intellectual Property
News headline image
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗
This biotech has candidates in late-stage clinical development. 
Via The Motley Fool
News headline image
The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally... 
Via MarketMinute
Topics Economy
News headline image
VIX Tumbles as Trump Rescinds Greenland Tariff Threats
Wall Street witnessed a surge in risk-on sentiment today as the Cboe Volatility Index (VIX) fell by over 5%, closing at 15.94. The decline marks a sharp reversal from the "Greenland Chill" that gripped... 
Via MarketMinute
Topics Bonds Government Stocks
News headline image
Arctic Ultimatum: Trump’s Greenland Tariff Threat Triggers $4,700 Gold Surge and 870-Point Dow Plunge
The global financial landscape was thrown into chaos on January 20, 2026, as President Donald Trump intensified his administration’s pursuit of Greenland, issuing a sweeping tariff ultimatum against... 
Via MarketMinute
Topics Economy Government Stocks
News headline image
2 Top Stocks to Double Up On Right Now ↗
When you find winning stocks, stick with them. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic ↗
Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration. 
Via Stocktwits
News headline image
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? ↗
Despite a challenging year, the company has a lot to look forward to in the coming years. 
Via The Motley Fool
News headline image
Is Oral Wegovy a Game Changer for Novo Nordisk? ↗
The past couple of years have been challenging for the company. But this could be the beginning of a new chapter. 
Via The Motley Fool
News headline image
Arctic Chill: Global Markets Reeling as Trump Demands Greenland Purchase with Massive Tariff Threats
WASHINGTON D.C. / NEW YORK — Global financial markets were plunged into a state of "Arctic uncertainty" this Tuesday, January 20, 2026, as U.S. stock futures cratered following a weekend of... 
Via MarketMinute
Topics Economy Government Stocks
News headline image
The Arctic Gambit: Trump’s National Security Push for Greenland Sparks Diplomatic Crisis and Market Volatility
In a move that has sent shockwaves through both the halls of the United Nations and the trading floors of Wall Street, President Donald Trump has officially designated the acquisition of Greenland as a... 
Via MarketMinute
Topics Economy Electric Vehicles Government
News headline image
The Battle for the White Coat: OpenAI and Anthropic Reveal Dueling Healthcare Strategies
In the opening weeks of 2026, the artificial intelligence industry has moved beyond general-purpose models to a high-stakes "verticalization" phase, with healthcare emerging as the primary... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
Via MarketBeat
Topics ETFs
News headline image
Anthropic’s New Specialized Healthcare Tiers: A New Era for AI-Driven Diagnostics and Medical Triage
On January 11, 2026, Anthropic, the AI safety and research company, officially unveiled its most significant industry-specific expansion to date: specialized healthcare and life sciences tiers for its... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins
As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin... 
Via Finterra
Topics Economy
News headline image
The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its... 
Via Finterra
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Prediction: 2026 Will Be the Year of Eli Lilly ↗
A catalyst lies just ahead. 
Via The Motley Fool
News headline image
The Arctic Ultimatums: Trump’s Greenland Bid Sparks Global Trade War and NATO Crisis
WASHINGTON D.C. — In a dramatic escalation of his "America First" foreign policy, President Donald Trump has moved beyond mere interest to a formal demand for the acquisition of Greenland, threatening... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? ↗
The choice isn't that hard. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.